Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity

References

• WHO guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series, No. 927, 2005
   Google Scholar
• Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997; 51:51-78; PMID:9343347; http://dx.doi.org/10.1146/annurev.micro.51.1.151
   PubMed Web of Science ®Google Scholar
• Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 1993; 90:4171-5; PMID:8387212; http://dx.doi.org/10.1073/pnas.90.9.4171
   PubMed Web of Science ®Google Scholar
• Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 1999; 96:13910-3; PMID:10570172; http://dx.doi.org/10.1073/pnas.96.24.13910
   PubMed Web of Science ®Google Scholar
• Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987; 41:409-33; PMID:3318675; http://dx.doi.org/10.1146/annurev.mi.41.100187.002205
   PubMed Web of Science ®Google Scholar
• Madden JC, Hewitt M, Przybylak K, Vandbriel RJ, Piersma AH, Cronin MTD. Strategies for the optimisation for in vivo experiments in accordance with the 3Rs philosophy. Regul Toxicol Pharmacol 2012; 63:140-54; PMID:22446816; http://dx.doi.org/10.1016/j.yrtph.2012.03.010
   PubMed Web of Science ®Google Scholar
• Das RG, Fry D, Preziosi R, Hudson M. Planning for reduction. ATLA 2009; 37:27-32; PMID:19292573
   PubMedGoogle Scholar
• Kilkenny C, Parsons N, Kadiszewsky E, Festing MFW, Cuthill IC, Fry D, Hutton J, Altman DG. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PloS One 2009; 4, e7824; PMID:19956596; http://dx.doi.org/10.1371/journal.pone.0007824
   PubMed Web of Science ®Google Scholar
• Shaw R, Festing MFW, Peers I, Furlong L. Use of factorial designs to optimize animal experiments and reduce animal use. ILAR J 2002; 43:223-32; PMID:12391398; http://dx.doi.org/10.1093/ilar.43.4.223
   PubMedGoogle Scholar
• Carbone KM, Rubin S. Mumps virus. In: Knipe DM, Howley PM, editors. Fields Virology, 5th ed. Lippincott Williams & Wilkins, 2007, p. 1528-50.
   Google Scholar
• Watson-Creed G, Saunders A, Scott J, Lowe L, Pettipas J, Hatchette TF. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ 2006; 175:483-8; PMID:16940266; http://dx.doi.org/10.1503/cmaj.060660
   PubMed Web of Science ®Google Scholar
• Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, et al. Recent resurgence of mumps in the United States. New Engl J Med 2008; 358:1580-9; PMID:18403766; http://dx.doi.org/10.1056/NEJMoa0706589
   PubMed Web of Science ®Google Scholar
• Rota JS, Turner JC, Yost-Daljev MK, Freeman M, Toney DM, Meisel E, Williams N, Sowers SB, Lowe L, Rota PA, et al. Investigation of a mumps outbreak among university students with two measles-mumps rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol 2009; 81:1819-25; PMID:19697404; http://dx.doi.org/10.1002/jmv.21557
   PubMed Web of Science ®Google Scholar
• Stein-Zamir C, Shoob H, Abramson N, Tallen-Gozani E, Sokolov I, Zentner G. Mumps outbreak in Jerusalem affecting mainly male adolescents. Eurosurveillance 2009; 14:19940
   Google Scholar
• Carr MJ, Moss E, Waters A, Dean J, Jin L, Coughlan S, Connell J, Hall WW, Hassan J. Molecular epidemiological evaluation of the recent resurgence in mumps virus infections in Ireland. J Clin Microbiol 2010; 48:3288-94; PMID:20660212; http://dx.doi.org/10.1128/JCM.00434-10
   PubMed Web of Science ®Google Scholar
• Echevarría JE, Castellanos A, Sanz JC, Pérez C, Palacios G, Martínez de Aragón MV, Pena Rey I, Mosquera M, de Ory F, Royuela E. Circulation of mumps virus genotypes in Spain from 1996 to 2007. J Clin Microbiol 2010; 48:1245-54; PMID:20107099; http://dx.doi.org/10.1128/JCM.02386-09
   PubMed Web of Science ®Google Scholar
• Otto W, Mankertz A, Santibanez S, Saygili H, Wenzel J, Jilg W, Wieland WF, Borgmann S. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Eurosurveillance 2010; 15:19748; PMID:21172171
   PubMedGoogle Scholar
• Whelan J, van Binnendijk R, Greenland K, Fanoy E, Khargi M, Yap K, Boot H, Veltman N, Swaan C, van der Bij A, de Melker H, Hahné S. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010. Eurosurveillance 2010; 15:19554; PMID:20460086
   PubMedGoogle Scholar
• Rubin SA, Afzal MA. Neurovirulence safety testing of mumps vaccines - historical perspective and current status. Vaccine 2011; 29:2850-5; PMID:21334386; http://dx.doi.org/10.1016/j.vaccine.2011.02.005
   PubMed Web of Science ®Google Scholar
• Houard D, Varsanyi TM, Milican F, Norrby E, Bollen A. Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors. J Gen Virol 1995; 76:421-3; PMID:7844562; http://dx.doi.org/10.1099/0022-1317-76-2-421
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9; PMID:18558875; http://dx.doi.org/10.1086/589862
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
   PubMed Web of Science ®Google Scholar
• Latner DR, McGrew M, Williams NJ, Sowers SB, Bellini WJ, Hickman CJ. Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol 2014; 21:286-97; PMID:24371258; http://dx.doi.org/10.1128/CVI.00621-13
   PubMed Web of Science ®Google Scholar
• Poethko-Mueller C, Mankertz A. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One 2012; 7(8):e42867; PMID:22880124; http://dx.doi.org/10.1371/journal.pone.0042867
   PubMedGoogle Scholar
• Usonis V, Bakasenas V, Denis M. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection 2001; 29:159-62; PMID:11440387; http://dx.doi.org/10.1007/s15010-001-1098-7
   PubMed Web of Science ®Google Scholar
• Nöjd J, Tecle T, Samuelsson A, Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps genotype. Vaccine 2001; 19:1727-31; PMID:11166897; http://dx.doi.org/10.1016/S0264-410X(00)00392-3
   PubMed Web of Science ®Google Scholar
• Flynn M, Mahon BP. Cell mediated and humoral immune responses to mumps virus: recent developments. Rec Res Dev Virol 2003; 5:97-115
   Google Scholar
• Eriksson L, Johansson E, Kettaneh-Wold N, Wikström C, Wold S. Design of Experiments, Principles and Applications, Stockholm: Umetrics AB, 2000.
   Google Scholar
• Araujo P. Key aspects of analytical method validation and linearity evaluation. J Chromatogr B 2009; 877:2224-34; PMID:18929516; http://dx.doi.org/10.1016/j.jchromb.2008.09.030
   PubMed Web of Science ®Google Scholar
• Dejaegher B, Vander Heyden Y. Ruggedness and robustness testing. J Chromatogr A 2007; 1158:138-57; PMID:17379230; http://dx.doi.org/10.1016/j.chroma.2007.02.086
   PubMed Web of Science ®Google Scholar
• Krzywinski M, Altman N. Two-factor designs. Nat Methods 2014; 11:699-700
   PubMed Web of Science ®Google Scholar
• Young CR, Ebringer A, Archer JR. Antigen dose and strain variation as factors in the genetic control of the immune response to sperm whale myoglobin. Immunology 1978; 34:571-9; PMID:417022
   PubMed Web of Science ®Google Scholar
• Mumps Vaccine (live). 01/2008:0538. In: European Pharmacopoeia 8th Edition, Strasbourg: Council of Europe, 2013.
   Google Scholar
• Hanly WC, Artwohl JE, Bennett BT. Review of polyclonal antibody production procedures in mammals and poultry. ILAR J 1995; 37:93-118; PMID:11528030; http://dx.doi.org/10.1093/ilar.37.3.93
   PubMedGoogle Scholar
• Hunt JD, Brown LE, Jackson DC. Antigenic competition. eLS 2001
   Google Scholar
• Ivancic J, Kosutic Gulija T, Forcic D, Baricevic M, Jug R, Mesko-Prejac M, Mazuran R. Genetic characterization of L-Zagreb mumps vaccine strain. Virus Res 2005; 109:95-105; PMID:15826917
   PubMed Web of Science ®Google Scholar
• Ivancic-Jelecki J, Santak M, Forcic D. Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains. InfectGenet Evol 2008; 8:603-13; PMID:18508415
   PubMed Web of Science ®Google Scholar
• Šantak M, Lang-Balija M, Inavcic-Jelecki J, Košutić-Gulija T, Ljubin-Sternak S, Forcic D. Antigenic differences between vaccine and circulating wild-type mumps viruses decreases neutralization capacity of vaccine-induced antibodies. Epidemiol Infect 2013; 141:1298-309
   PubMed Web of Science ®Google Scholar
• Rubin S, Mauldin J, Chumakov K, Vanderzanden J, Iskow R, Carbone K. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2006; 24:2662-8; PMID:16309801
   PubMed Web of Science ®Google Scholar
• Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005; 51: 294-8; PMID:16291282
   PubMed Web of Science ®Google Scholar
• Toscani L, Batou M, Bouvier P, Schlaepfer A. Comparison of the efficacy of various strains of mumps vaccine: a study in schools. Soz Praventiv Med 1996; 41:341-7
   PubMedGoogle Scholar
• Chamot E, Toscani L, Egger P, Germann D, Bourquin C. [Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)]. Rev Epidemiol Sante Publique 1998; 46:100-7; PMID:9592852
   PubMed Web of Science ®Google Scholar
• Schloegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL. Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: cohort study. BMJ 1999; 519:352-3
   Google Scholar
• Rubin SA, Afzal MA, Powell CL, Bentley ML, Auda GR, Taffs RE, Carbone KM. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 2005; 191:1123-8; PMID:15747248
   PubMed Web of Science ®Google Scholar
• Forcic D, Kosutić-Gulija T, Santak M, Jug R, Ivancic-Jelecki J, Markusic M, Mazuran R. Comparisons of mumps virus potency estimates obtained by 50% cell culture infective dose assay and plaque assay. Vaccine 2010; 28:1887-92; PMID:19961964
   PubMed Web of Science ®Google Scholar
• Cross G. Hemagglutination inhibition assay. Semin Avian Exot Pet 2002; 11:15-8
   Web of Science ®Google Scholar